Pooled analysis of two Phase III Trials shows Halaven® (Eribulin) improves survival in advanced breast cancer
Significant survival benefit observed in women with HER2 negative breast cancer – ASCO Press Release.
Significant survival benefit observed in women with HER2 negative breast cancer – ASCO Press Release.
Pivotal phase III data for lenvatinib to be presented in a Head and Neck Cancer oral session at American Society of Clinical Oncology congress (ASCO) – Press Release.
by Bruce Sylvester – Researchers report that a pooled analysis of two major trials suggests that short- and long-term outcomes of neoadjuvant chemotherapy followed by chemoradiotherapy in high-risk… read more.
by Bruce Sylvester – Gender and tumor location predict efficacy in first-line treatment metastatic colorectal cancer, researchers reported a poster presentation at ASCO 2014.
Non-invasive focused ultrasound thermal therapy reduces pain from bone metastases. When cancer progresses and spreads to the bone, patients often suffer debilitating pain. Now, a new phase III… read more.
by Bruce Sylvester – The presence of the single nucleotide polymorphism (SNP) rs895374, located in UbcH7, an E2 ligase conducting neddylation of HECT E3 ligases involved in EGFR… read more.
by Bruce Sylvester – Intermittent strategies for delivering systemic treatment in metastatic colorectal cancer show no clinically significant superiority in overall survival rates when compared to continuous delivery,… read more.
by Bruce Sylvester – In the FIRE 3 trial, clinicians favored the use of second-line antibodies in patients with KRAS wild-type metastatic colorectal cancer (mCRC) with shorter first-line… read more.
by Bruce Sylvester – KRAS exon 2 mutations are independent predictors of time to recurrence or disease-free survival among patients with stage III distal colon cancer who are… read more.
by Bruce Sylvester – Metastatic colorectal cancer patients who achieved early response to first-line chemotherapy also achieved significantly higher rates of prolonged survival, compared to patients who did… read more.
by Bruce Sylvester – Survival based on primary site of disease is not significantly different among metastatic colorectal cancer patients, Australian researchers reported in a poster presentation at… read more.
Adapted from Abstract 3506, which was submitted to ASCO Congress 2014 Treatment outcome according to tumour RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC)… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.